Abstract
Background: 1st and 2nd generation cephalosporins used for perioperative prophylaxis in orthopaedic surgery do not cover non-fermenting Gram-negative rods (NFR).
Methods: Epidemiological cohort study of adult patients operated for orthopedic infections between 2004 and 2014 with perioperative cefuroxim or vancomycin prophylaxis. Exclusion of polyneuropathic ischemic foot infections and septic bursitis cases.
Results: Of the total 1840 surgical procedures in the study, 430 grew Gram-negative pathogens (23%), of which 194 (11%) were due to NFR and 143 (8%) to Pseudomonas aeruginosa. Overall, 634 episodes (35%) involved orthopaedic implants (321 arthroplasties, 135 plates, 53 nails, and others). In multivariate analysis and group comparisons, especially preoperative antibiotic use (124/194 vs. 531/1456; p<0.01) was significantly associated with NFR.
Conclusions: Overall proportion of NFR oscillated between 9% and 13% among our orthopaedic infections. Variables associated with NFR were antibiotic use prior to hospitalization. The low infection rate of NFR following elective surgery and the community-based epidemiology, has led us to keep our standard perioperative prophylaxis unchanged.
Keywords: Orthopaedic infections, epidemiology, Gram-negative, non-fermenting rods, Pseudomonas aeruginosa
Introduction
We frequently see Gram-negative non-fermenting rods (NFR), such as Pseudomonas or Enterobacter spp, in orthopedic infections 1-5, e.g. after trauma 6,7 or open fractures 8. Simultaneously, we are witnessing a rising prevalence of extended-spectrum beta-lactamase producing-rods body carriage (ESBL) on orthopaedic wards 9. Some authors speculate that the number of orthopaedic infections due to these Gram-negative pathogens might rise in the future, especially if we consider the increasing number of elderly, diabetic 10, organ transplant 11 and oncologic persons 12 among our orthopaedic patients. According to the United States National Healthcare Safety Network, NFR infections rank fourth among the most important pathogens for all device-associated infections in the last decade 13. Based on expert recommendations, most centers use 1st and 2nd generation cephalosporins or vancomycin for perioperative prophylaxis 14. However, these antibiotics do not cover NFR or ESBL.
We investigate if subgroups of orthopaedic patients or procedures are particularly at risk for Gram-negative, and more specifically, NFR, ESBL or P. aeruginosa infections; eventually warranting an adaptation of antibiotic prophylaxis in some specific cases. Of note, we do not investigate outcomes of various Gram-negative infections, nor the incidence or Gram-negative nosocomial infections, which have been already described elsewhere 2,3,15-21.
Methods
We performed a retrospective cohort study of adult patients operated at Geneva University Hospitals between January 2004 and December 2014. Standard perioperative antibiotic prophylaxis was a single intravenous dose of 1.5g cefuroxim or 1g vancomycin. The infection database encompassed soft tissue, joint, bone and implant infections, including both community-acquired and nosocomial infections, and supported by the local Ethical Committee.
We defined an “orthopaedic infection” as the presence of intraoperative pus, together with other symptoms (new onset of pain, fever, redness, discharge, sinus track), and radiographic signs (implant loosening or presence of sequestrae). To avoid data clustering, we included only the first episode of the same infection and excluded recurrent episodes from further analysis. We also excluded pediatric cases, polyneuropathic or ischemic foot infections, such in diabetic patients, and septic bursitis cases, because these were considered as too different populations. We processed all specimens in the microbiology laboratory according to Clinical and Laboratory Standard's Institutes' recommendations 22 except for switching to EUCAST criteria (European Committee on Antimicrobial Susceptibility Testing) in spring 2014 23. The standard incubation period for cultures was 5 days.
We performed group comparisons using the Pearson χ2-test or the Wilcoxon rank-sum test. To adjust for case-mix, we performed an unmatched logistic regression analysis (outcome: Gram-negative infection). Independent variables with a p value ≤0.20 in univariate analysis were introduced stepwise into the multivariate analysis, by avoiding interactions. P values ≤0.05 were significant. We used STATA™ software (9.0; College Station, USA).
Results
In total, 2740 infection episodes were retrieved, of which 428 were diabetic foot infections and 472 septic bursitis cases, which were excluded from further analysis. An additional 261 patients were not operated and thus not followed-up by our service. The median age of the remaining 1840 episodes in the study was 57 years (range, 18-99 years). There were 652 females and 1188 males; 598 patients (33%) were immune-compromised (diabetes mellitus, solid organ or bone marrow transplants, untreated HIV disease, immune-depressive drugs, active cancer, cirrhosis CHILD C, dialysis, pregnancy, and splenectomy). Overall, 634 episodes involved implants: 321 arthroplasties, 135 plates, 53 nails, 31 spondylodesis and others. The number of bone and joint infections (including implants) was 1023 (56%), that of soft tissue infections 817. The median duration of antibiotic use prior to intraoperative sampling was 4 days; it occurred in 790 (43%) of all cases.
Gram-negative infections
Overall, 430 (24%) samples grew Gram-negative pathogens (Table 1), of which 194 (11%) were due to NFR (Table 2), 143 (8%) to P. aeruginosa (Table 3), and six (0.01%) to ESBL-producing gram-negative rods. The proportion of NFR among Gram-negative pathogens was 45% (258/568). We could not detect Gram-negative infection outbreaks throughout the entire study period 24. In multivariate analysis adjusting for case-mix, polymicrobial infections and prior antibiotic use were the only significant predictors (Table 4). These associations were similar for NFR and P. aeruginosa, without major differences between them (Tables 1-3).
Table 1.
Other pathogens | Gram-negative pathogens | ||
---|---|---|---|
n=1410 (77%) | p value | n=430 (23%) | |
Patient characteristics | |||
F:M (percentage of female) | 491:919 (35%) | ns | 161:269 (37%) |
Median age | 54 years | <0.01 | 61 years |
- Age < 51 years | 615 (44%) | <0.01 | 150 (35%) |
- Age 51 to 80 years | 638 (45%) | <0.01 | 226 (53%) |
- Age > 80 years | 157 (11%) | ns | 54 (13%) |
Median serum C-reactive protein level | 81 mg/L | ns | 88 mg/L |
- CRP < 51mg/L | 427 (30%) | <0.05 | 108 (25%) |
- CRP 51 to 200mg/L | 432 (31%) | 139 (32%) | |
- CRP > 200mg/L | 551 (39%) | 183 (43%) | |
Prior antibiotic use | 561 (40%) | <0.01 | 229 (53%) |
Median duration of prior antibiotic use | 4 days | ns | 5 days |
Immune compromised+ | 439 (31%) | 0.02 | 159 (37%) |
- Diabetes mellitus | 230 (16%) | <0.01 | 101 (24%) |
Type of infection | |||
Osteoarticular infections | 808 (57%) | <0.01 | 215 (50%) |
All implant-associated infections | 488 (35%) | ns | 146 (34%) |
- Prosthetic joint infections | 251 (18%) | ns | 70 (16%) |
- Spondylodesis infections | 20 (1%) | <0.05 | 11 (2%) |
- Nail infections | 40 (3%) | ns | 13 (3%) |
- Plate infections | 107 (8%) | ns | 28 (7%) |
Soft tissue abscess | 396 (28%) | ns | 102 (24%) |
Shoulder infections | 82 (6%) | <0.01 | 10 (2%) |
Spine infections | 20 (1%) | ns | 11 (3%) |
Polymicrobial infections | 188 (15%) | <0.01 | 207 (48%) |
ns = not significant
+ = diabetes, immune-suppressive medication, dialysis, active cancer, untreated HIV disease, cirrhosis CHILD C, pregnancy, splenectomy.
Table 2.
Other than non-fermenting rods | Non-fermenting rods | ||
---|---|---|---|
n=1646 (89%) | p value | n=194 (11%) | |
Patient characteristics | |||
F:M (percentage of female) | 497:957 (31%) | ns | 69:125 (36%) |
Median age | 56 years | ns | 61 years |
- Age ≤ 50 | 615 (42%) | 70 (36%) | |
- Age 51 to 80 | 668 (46%) | 100 (52%) | |
- Age > 80 | 173 (12%) | 24 (12%) | |
Median serum C-reactive protein level | 87 mg/L | ns | 86 mg/L |
- CRP < 51mg/L | 417 (29%) | ns | 47 (24%) |
- CRP 51 to 200mg/L | 455 (31%) | 61 (31%) | |
- CRP > 200mg/L | 584 (40%) | 86 (44%) | |
Prior antibiotic use | 531 (36%) | <0.01 | 124 (64%) |
Median duration of prior antibiotic use | 3 days | <0.01 | 7 days |
Immune-compromised+ | 471 (32%) | ns | 68 (35%) |
- Diabetes mellitus | 259 (18%) | ns | 43 (22%) |
Type of infection | |||
Osteoarticular infections | 824 (57%) | ns | 104 (54%) |
All implant-associated infections | 514 (35%) | ns | 82 (42%) |
- Prosthetic joint infections | 270 (19%) | ns | 31 (16%) |
- Spondylodesis infections | 23 (2%) | 0.05 | 7 (4%) |
- Nail infections | 44 (3%) | ns | 8 (4%) |
- Plate infections | 109 (7%) | ns | 22 (11%) |
Soft tissue abscess | 396 (27%) | ns | 43 (22%) |
Shoulder infections | 77 (5%) | 0.02 | 3 (2%) |
Spine infections | 68 (5%) | ns | 5 (3%) |
Polymicrobial infections | 305 (21%) | <0.01 | 90 (46%) |
ns = not significant
+ = diabetes, immune suppressive medication, dialysis, active cancer, untreated HIV disease, cirrhosis CHILD C, pregnancy, splenectomy
Table 3.
Other than Pseudomonas | Pseudomonas spp | ||
---|---|---|---|
n=1697 (92%) | p value | n=194 (8%) | |
Patient characteristics | |||
F:M (percentage of female) | 596:1101 (35%) | ns | 56:87 (39%) |
Median age | 56 years | ns | 56 years |
- Age < 51 | 705 (42%) | 60 (42%) | |
- Age 51 to 80 | 795 (47%) | 69 (51%) | |
- Age > 80 | 197 (12%) | 14 (10%) | |
Median serum C-reactive protein level | 87 mg/L | <0.01 | 66 mg/L |
- CRP < 51mg/L | 490 (29%) | 45 (31%) | |
- CRP 51 to 200mg/L | 527 (31%) | 44 (31%) | |
- CRP > 200mg/L | 680 (40%) | 54 (38%) | |
Prior antibiotic use | 712 (42%) | <0.01 | 78 (55%) |
Median duration of prior antibiotic use | 4 days | ns | 5 days |
Immune-compromised+ | 556 (33%) | ns | 42 (29%) |
- Diabetes mellitus | 306 (18%) | ns | 25 (17%) |
Type of infection | |||
Osteoarticular infections | 952 (56%) | ns | 71 (50%) |
All implant-associated infections | 588 (35%) | ns | 46 (32%) |
- Prosthetic joint infections | 308 (18%) | <0.01 | 13 (9%) |
- Spondylodesis infections | 25 (1%) | 0.02 | 6 (4%) |
- Nail infections | 49 (3%) | ns | 4 (3%) |
- Plate infections | 123 (7%) | ns | 12 (8%) |
Soft tissue abscess | 472 (28%) | 0.01 | 26 (18%) |
Shoulder infections | 91 (5%) | 0.01 | 1 (1%) |
Spine infections | 74 (4%) | ns | 3 (2%) |
Polymicrobial infections | 324 (22%) | <0.01 | 71 (50%) |
ns = not significant
+ = diabetes, immune-suppressive medication, dialysis, active cancer, untreated HIV disease, cirrhosis CHILD C, pregnancy, splenectomy.
Table 4.
Univariate analysis | Multivariate analysis | |
---|---|---|
Odds ratio with 95% confidence intervals |
Odds ratio with 95% confidence intervals |
|
Female sex | 1.1, 0.9-1.4 | n.a. |
Median age | 1.0, 1.0-1.0 | 1.0, 1.0-1.0 |
Serum C-reactive protein level at admission | 1.0, 1.0-1.0 | n.a. |
Immune-compromised | 1.3, 1.0-1.6 | 1.1, 0.9-1.5 |
- diabetes mellitus | 1.6, 1.2-2.1 | n.a. |
Bacteraemia | 0.7, 0.5-1.1 | 0.7, 0.5-1.1 |
Presence of osteosynthesis material | 1.0, 0.8-1.2 | 1.0, 0.7-1.4 |
- total prosthetic joint | 0.9, 0.7-1.2 | 1.0, 0.7-1.5 |
- nails | 1.1, 0.6-2.0 | n.a. |
- plates | 0.8, 0.6-1.3 | n.a. |
Prior antibiotic use | 1.7, 1.2-2.4 | 2.0, 1.5-2.5 |
Bone and joint infection | 0.7, 0.6-1.0 | n.a. |
Shoulder infections | 0.5, 0.2-0.9 | n.a. |
Spine infections | 0.8, 0.4-1.4 | n.a. |
Presence of abscess | 0.8, 0.6-1.1 | n.a. |
Polymicrobial infections | 5.0, 3.8-6.4 | 4.9, 3.8-6.3 |
n.a.= analysis not performed. Only results in bold and italic are statistically significant (two-sided p<0.05)
Discussion
In this 11-year single-centre cohort of 1840 operated orthopaedic infections, we witnessed an overall proportion of 24% for Gram-negative pathogens, 11% for NFR, and 8% for P. aeruginosa. ESBL infections were quasi inexistent. Of note, even if the proportion of NFR among all infections ranged around 10%, its proportion among Gram-negative pathogens was 45%. Our 45% are consistent with the literature reporting NFR proportions of 49% 17, 51% 16 or 53% 18 among Gram-negative microorganisms.
Thus, a broader antibiotic prophylaxis would make sense if Gram-negative infections were expected in elective surgery, which, however, we found only in the substrata of polymicrobial infections and those with prior antibiotic use. These situations were mainly encountered in cases of community-acquired infections that failed conservative treatment prior to hospitalization. In contrast, elective osteoarticular, prosthetic joint and implant-related infections lacked associations with Gram-negative bacteria, which suggest a true lack of genuine Gram-negative association.
In conclusion, with a low proportion of NFR and ESBL, and their striking association with community-acquired infections with prior antibiotic intake, we have currently kept our standard perioperative prophylaxis unchanged and continue to survey.
Acknowledgments
We thank to the Laboratory of Clinical Microbiology and the Orthopaedic Service for their valuable collaboration.
Preliminary results have been presented at the 3rdInternational Conference of Prevention and Infection Control (ICPIC), 16-19 June 2015, Geneva, Switzerland, and at the Annual Meeting of the Swiss Society for Infectious Diseases, 2-4 September 2015, Interlaken, Switzerland.
References
- 1.Khosravi AD, Ahmadi F, Salmanzadeh S, Dashtbozorg A, Montazeri EA. Study of bacteria Isolated from Orthopaedic Implant Infections and their Antimicrobial Susceptibility Pattern. Microbiol Research J. 2009;4:158–63. [Google Scholar]
- 2.Seghrouchni K, van Delden C, Dominguez D. et al. Remission after treatment of osteoarticular infections due to Pseudomonas aeruginosa versus Staphylococcus aureus: a case-controlled study. Int Orthop. 2012;36:1065–71. doi: 10.1007/s00264-011-1366-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Uçkay I, Bernard L. Gram-negative versus gram-positive prosthetic joint infections. Clin Infect Dis. 2010;50:795. doi: 10.1086/650540. [DOI] [PubMed] [Google Scholar]
- 4.Valour F, Dutronc H, Dinh A, Cazorla C, Pavèse P, Lesens O, Uçkay I, Chidiac C, Ferry T. Difficult-to-treat Gram-negative bone and joint infections: efficacy and safety of prolonged intravenous colistin. Int J Antimicrob Agents. 2013;41:197–9. doi: 10.1016/j.ijantimicag.2012.09.016. [DOI] [PubMed] [Google Scholar]
- 5.Tucaliuc D, Alexa O, Tuchiluş CG, Ursu RG, Tucaliuc ES, Jelihovsky I, Iancu LS. Antibiotic resistance spectrum of non fermenting gram-negative bacilli isolated in the orthopedic traumatology clinic of "Sf. Spiridon" clinical emergency hospital Iaşi. Rev Med Chir Soc Med Nat Iasi. 2015;119:536–43. [PubMed] [Google Scholar]
- 6.Di Benedetto C, Hoffmeyer P, Lew D, Uçkay I. Post-traumatic septic arthritis. Eur Musculoskelet Rev. 2012;7:1–5. [Google Scholar]
- 7.Uçkay I, Sax H, Harbarth S. et al. Multi-resistant infections in repatriated patients after natural disasters: lessons learned from the 2004 tsunami for hospital infection control. J Hosp Infect. 2008;68:1–8. doi: 10.1016/j.jhin.2007.10.018. [DOI] [PubMed] [Google Scholar]
- 8.Gonzalez A, Suvà D, Dunkel N, Nicodème JD, Lomessy A, Lauper N, Rohner P, Hoffmeyer P, Uçkay I. Are there clinical variables determining antibiotic prophylaxis-susceptible versus resistant infection in open fractures? Int Orthop. 2014;38:2323–7. doi: 10.1007/s00264-014-2395-x. [DOI] [PubMed] [Google Scholar]
- 9.Agostinho A, Renzi G, Haustein T. et al. Epidemiology and acquisition of extended-spectrum beta-lactamase-producing Enterobacteriaceae in a septic orthopedic ward. SpingerPlus. 2013;2:91. doi: 10.1186/2193-1801-2-91. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Al-Mayahi M, Cian A, Kressmann B, de Kalbermatten B, Rohner P, Egloff M, Jaafar J, Malacarne S, Miozzari HH, Uçkay I. Associations of diabetes mellitus with orthopaedic infections. Infect Dis (Lond) 2016;48:70–3. doi: 10.3109/23744235.2015.1082620. [DOI] [PubMed] [Google Scholar]
- 11.Vergidis P, Lesnick TG, Kremers WK, Razonable RR. Prosthetic joint infection in solid organ transplant recipients: a retrospective case-control study. TransplInfect Dis. 2012;14:380–6. doi: 10.1111/j.1399-3062.2011.00708.x. [DOI] [PubMed] [Google Scholar]
- 12.Mavrogenis AF, Papagelopoulos PJ, Coll-Mesa L, Pala E, Guerra G, Ruggieri P. Infected tumor prostheses. Orthopedics. 2011;34:991–8. doi: 10.3928/01477447-20111021-24. [DOI] [PubMed] [Google Scholar]
- 13.Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA. et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008;29:996–1011. doi: 10.1086/591861. [DOI] [PubMed] [Google Scholar]
- 14.Uçkay I, Hoffmeyer P, Lew D, Pittet D. Prevention of surgical site infections in orthopaedic surgery and bone trauma: state-of-the-art update. J Hosp Infect. 2013;84:5–12. doi: 10.1016/j.jhin.2012.12.014. [DOI] [PubMed] [Google Scholar]
- 15.Bulla F, Filippini P. Prosthetic joint infections by multi-drug resistant bacteria. Infez Med. 2010;18:5–11. [PubMed] [Google Scholar]
- 16.Hsieh PH, Lee MS, Hsu KY, Chang YH, Shih HN, Ueng SW. Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis. 2009;49:1036–43. doi: 10.1086/605593. [DOI] [PubMed] [Google Scholar]
- 17.Martínez-Pastor JC, Muñoz-Mahamud E, Vilchez F, García-Ramiro S, Bori G, Sierra J, Martínez JA, Font L, Mensa J, Soriano A. Outcome of acute prosthetic joint infections due to gram-negative bacilli treated with open debridement and retention of the prosthesis. Antimicrob Agents Chemother. 2009;53:4772–77. doi: 10.1128/AAC.00188-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Aboltins CA, Dowsey MM, Buising KL, Peel TN, Daffy JR, Choong PF. et al. Gram-negative prosthetic joint infection treated with debridement, prosthesis retention and antibiotic regimens including a fluoroquinolone. Clin Microbiol Infect. 2011;17:862–7. doi: 10.1111/j.1469-0691.2010.03361.x. [DOI] [PubMed] [Google Scholar]
- 19.Uçkay I, Lübbeke A, Harbarth S. et al. Low risk of methicillin-resistant Staphylococcus aureus infection following elective total joint arthroplasty: a 12-year experience. Ann Med. 2011;44:360–8. doi: 10.3109/07853890.2010.550932. [DOI] [PubMed] [Google Scholar]
- 20.Al-Mayahi M, Betz M, Müller DA, Stern R, Tahintzi P, Bernard L, Hoffmeyer P, Suvà D, Uçkay I. Remission rate of implant-related infections following revision surgery after fractures. Int Orthop. 2013;37:2253–8. doi: 10.1007/s00264-013-2092-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Zmistowski B, Fedorka CJ, Sheehan E, Deirmengian G, Austin M, Parvizi J. Prosthetic joint infection caused by Gram-negative organisms. J Arthroplasty. 2011;26:104–8. doi: 10.1016/j.arth.2011.03.044. [DOI] [PubMed] [Google Scholar]
- 22.Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 17th Informational Supplement M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute; 2007. [Google Scholar]
- 23.European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 4. European Committee on Antimicrobial Susceptibility Testing; 2014. [Google Scholar]
- 24.Uçkay I, Betz M, Vaudaux P. et al. Is there a significant seasonality in the occurrence of osteoarticular infections? Infect Dis (Lond) 2015;47:252–4. doi: 10.3109/00365548.2014.979436. [DOI] [PubMed] [Google Scholar]